Valganciclovir
ApprovedWithdrawn 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Giant Lymph Node Hyperplasia
Conditions
Giant Lymph Node Hyperplasia
Trial Timeline
Dec 1, 2008 → May 1, 2009
NCT ID
NCT00361933About Valganciclovir
Valganciclovir is a approved stage product being developed by Roche for Giant Lymph Node Hyperplasia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00361933. Target conditions include Giant Lymph Node Hyperplasia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00002222 | Pre-clinical | Completed |
| NCT00017784 | Phase 3 | UNKNOWN |
| NCT01663740 | Approved | Completed |
| NCT00361933 | Approved | Withdrawn |
| NCT00275314 | Phase 3 | Terminated |
| NCT00227370 | Phase 3 | Completed |
| NCT00374686 | Pre-clinical | Completed |
| NCT00275665 | Phase 3 | Completed |
Competing Products
20 competing products in Giant Lymph Node Hyperplasia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| prednisone | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Pexidartinib | Daiichi Sankyo | Phase 2 | 52 |
| Pexidartinib | Daiichi Sankyo | Phase 3 | 77 |
| Pexidartinib | Daiichi Sankyo | Approved | 85 |
| Baricitinib | Eli Lilly | Phase 2 | 52 |
| Upadacitinib + Corticosteroid (CS) | AbbVie | Phase 3 | 77 |
| dovitinib | Novartis | Phase 2 | 52 |
| Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c. | Novartis | Phase 3 | 77 |
| Secukinumab 300 mg, s.c. + Prednisolone + Placebo | Novartis | Phase 2 | 52 |
| Secukinumab | Novartis | Phase 1 | 33 |
| Secukinumab 300 mg + Secukinumab 150 mg | Novartis | Phase 3 | 77 |
| Tocilizumab + Placebo | Roche | Phase 3 | 77 |
| Tocilizumab + Prednisone | Roche | Approved | 85 |
| Tocilizumab | Roche | Phase 3 | 77 |
| Tocilizumab | Roche | Phase 1 | 33 |
| Tocilizumab + Prednisone + Tocilizumab Placebo + Prednisone Placebo + Corticosteroids + Methotrexate | Roche | Phase 3 | 77 |
| Tocilizumab + Glucocorticoids (GCs) + Placebo + Glucocorticoids (GCs) | Roche | Phase 2 | 52 |
| tocilizumab and IV steroids combination | Roche | Phase 2 | 52 |
| Denosumab | Amgen | Approved | 84 |
| Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] | Amgen | Phase 2 | 51 |